High-efficiency wild-type-free AAV helper functions

• US 6,001,650 A
• Filed: 08/28/1998
• Issued: 12/14/1999
• Est. Priority Date: 08/03/1995
• Status: Expired due to Term

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Avigen,Inc. (Medicinova Inc)
• Inventors: Colosi, Peter
• Primary Examiner(s): Degen, Nancy
• Assistant Examiner(s): SCHWARTZMAN, ROBERT A
• Application Number:
  US09/143,270
• Time in Patent Office: 473 Days
• Field of Search: 435/320.1, 435/325, 435/369, 536/23.72
• US Class Current: 435/369
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14152 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2750/14162 by genetic engineering
• CPC Class Codes: C12N 2800/30 Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
• CPC Class Codes: C12N 2840/20 translation of more than one cistron
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention provides methods and compositions for producing high titer, wild-type-free preparations of recombinant AAV ("rAAV") virions. The compositons of the present invention include novel nucleic acids encoding AAV helper functions and AAV helper function vectors. The present invention also includes host cells transfected by the claimed nucleic acids, methods of using the claimed vectors, and rAAV virions produced by such methods.

Claims

1. A nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, such that the modified AAV p5 promoter region no longer functions in transcription initiation.

2. An AAV helper function vector comprising the nucleic acid molecule of claim 1.

3. A host cell comprising the nucleic acid molecule of claim 1.

4. The AAV helper function vector of claim 2, wherein the vector is a plasmid.

5. The AAV helper function vector of claim 2, further comprising one or more accessory function genes.

6. A method of producing recombinant AAV (rAAV) virions comprising:

(a) introducing an AAV vector into a suitable host cell;

(b) introducing the AAV helper function vector of claim 2 into the host cell;

(c) expressing accessory functions in the host cell; and

(d) culturing the host cell to produce rAAV virions.

7. The host cell of claim 3 further comprising accessory function genes.

8. A recombinant AAV (rAAV) virion produced by the method of claim 6.

9. A nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, wherein the modified p5 promoter region lacks an intact TATA box.

10. An AAV helper function vector comprising the nucleic acid molecule of claim 9.

11. A host cell of the nucleic acid molecule of claim 9.

12. The nucleic acid molecule of claim 9, wherein the nucleotide sequence is arranged in the nucleic acid molecule such that the modified AAV p5 promoter region is situated 3'"'"' relative to the rep coding region.

13. The nucleic acid molecule of claim 9, wherein the nucleotide sequence is arranged in the nucleic acid molecule such that the modified AAV p5 promoter region is situated 3'"'"' relative to the cap coding region.

14. The AAV helper function vector of claim 10, wherein the vector is a plasmid.

15. The AAV helper function vector of claim 10, further comprising one or more accessory function genes.

16. A method of producing recombinant AAV (rAAV) virions comprising:

(a) introducing an AAV vector into a suitable host cell;

(b) introducing the AAV helper function vector of claim 10 into the host cell;

(c) expressing accessory functions in the host cell; and

(d) culturing the host cell to produce rAAV virions.

17. The host cell of claim 11 further comprising accessory function genes.

18. An AAV helper function vector comprising the nucleic acid molecule of claim 12.

19. A host cell comprising the nucleic acid molecule of claim 12.

20. A recombinant AAV (rAAV) virion produced by method of claim 16.

21. The AAV helper function vector of claim 18, wherein the vector is a plasmid.

22. The AAV helper function vector of claim 18, further comprising one or more accessory function genes.

23. A method of producing recombinant AAV (rAAV) virions comprising:

(a) introducing an AAV vector into a suitable host cell;

(b) introducing the AAV helper function vector of claim 18 into the host cell;

(c) expressing accessory functions in the host cell; and

(d) culturing the host cell to produce rAAV virions.

24. The host cell of claim 19 further comprising accessory function genes.

25. A recombinant AAV (rAAV) virion produced by the method of claim 23.